- Home
- UFCS vs CRMD Comparison
UFCS vs CRMD Comparison
Compare UFCS & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UFCS
- CRMD
- Stock Information
- Founded
- UFCS 1946
- CRMD 2006
- Country
- UFCS United States
- CRMD United States
- Employees
- UFCS N/A
- CRMD 82
- Industry
- UFCS Property-Casualty Insurers
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- UFCS Finance
- CRMD Health Care
- Exchange
- UFCS Nasdaq
- CRMD Nasdaq
- Market Cap
- UFCS 642.7M
- CRMD 738.4M
- IPO Year
- UFCS N/A
- CRMD 2010
- Fundamental
- Price
- UFCS $26.66
- CRMD $12.17
- Analyst Decision
- UFCS Hold
- CRMD Strong Buy
- Analyst Count
- UFCS 1
- CRMD 6
- Target Price
- UFCS $26.00
- CRMD $15.67
- AVG Volume (30 Days)
- UFCS 146.7K
- CRMD 1.3M
- Earning Date
- UFCS 02-11-2025
- CRMD 03-11-2025
- Dividend Yield
- UFCS 2.38%
- CRMD N/A
- EPS Growth
- UFCS N/A
- CRMD N/A
- EPS
- UFCS 1.94
- CRMD N/A
- Revenue
- UFCS $1,207,451,000.00
- CRMD $12,262,234.00
- Revenue This Year
- UFCS N/A
- CRMD N/A
- Revenue Next Year
- UFCS $11.31
- CRMD $300.00
- P/E Ratio
- UFCS $13.85
- CRMD N/A
- Revenue Growth
- UFCS 10.95
- CRMD 41184.20
- 52 Week Low
- UFCS $18.04
- CRMD $2.89
- 52 Week High
- UFCS $31.70
- CRMD $13.85
- Technical
- Relative Strength Index (RSI)
- UFCS 40.94
- CRMD 69.19
- Support Level
- UFCS $25.20
- CRMD $7.91
- Resistance Level
- UFCS $29.01
- CRMD $11.50
- Average True Range (ATR)
- UFCS 0.71
- CRMD 0.68
- MACD
- UFCS -0.22
- CRMD 0.46
- Stochastic Oscillator
- UFCS 37.06
- CRMD 82.64
About UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.